ClinicalTrials.gg
CompletedNCT02046603ACT-MOVEUpdated Dec 7, 2018Results posted

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent

A Phase 3 interventional study of Tocilizumab and DMARDs in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 38 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
162
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.

Enrollment
35th of 110
162 · median 97
Started
2014
with 8 others
Phase 3
65 of 110
none open now
Registered
84th of 110
by date
Lead sponsor
67 of 110
Hoffmann-La Roche

Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 35th largest by enrollment, is one of 9 that started in 2014, is one of 65 in phase 3, and was the 84th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About tocilizumab

tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing tocilizumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This open-label study will evaluate the efficacy and safety of tocilizumab as monotherapy or in combination with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) in participants with active rheumatoid arthritis (RA) and an inadequate response to current non-biologic DMARD therapy or the first anti-tumour necrosis factor (anti-TNF) agent. Participants will receive tocilizumab 162 milligrams (mg) subcutaneously once a week for 52 weeks.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria
  • Participants who have an inadequate response to current non-biologic DMARD therapy or the first anti-TNF agent (in monotherapy or in combination with MTX or other non-biologic DMARDs). Inadequate response to anti-TNF treatment is defined as DAS28 score improvement of less than 1.2 or participants achieving a DAS28 score improvement of 1.2 but not achieving low disease activity (current DAS28-ESR above 3.2) according to a treat-to-target strategy and have not been previously exposed to treatment with tocilizumab. Inadequate response to non-biologic DMARD therapy will be assessed according to local guidelines and the participants will need to be eligible for biologic therapy according to local guidelines
  • Oral (≤10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to recommended dose) are permitted if on stable dose regimen for greater than or equal to [≥] 4 weeks prior to baseline
  • Permitted non-biologic DMARDs are allowed if on stable dose for at least 4 weeks prior to baseline
  • Receiving treatment on an outpatient basis, not including tocilizumab
  • Females of and males with female partners of childbearing potential must agree to use reliable means of as defined by protocol during the study and for at least 3 months following the last dose of tocilizumab

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline
  • Rheumatic disease other than RA
  • Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16
  • Prior history of or current inflammatory joint disease other than RA
  • Exposure to tocilizumab either intravenous or SC at any time prior to baseline
  • Treatment with any agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) of screening
  • Intra-articular or parenteral within 4 weeks prior to baseline
  • History of severe allergic or anaphylactic reactions to human, humanized or murine monoclonal antibodies
  • Known active current or history of recurrent infections
  • Major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
  • Active tuberculosis (TB) requiring treatment within the previous 3 years
  • Positive for or virus infection
  • Primary or secondary immunodeficiency (history of or currently active)
  • Pregnant or lactating women
  • Inadequate hematologic, renal or liver function
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
162 participants (actual)

Study arms

  • Experimental
    Tocilizumab Monotherapy

    Participants will receive a weekly SC injection of tocilizumab 162 mg as monotherapy for 52 weeks.

    Drug: Tocilizumab

  • Experimental
    Tocilizumab in Combination With Methotrexate or Other DMARDs

    Participants will receive a weekly SC injection of tocilizumab 162 mg in combination with methotrexate or other non-biologic DMARDs for 52 weeks.

    Drug: Tocilizumab · Drug: DMARDs · Drug: Oral Corticosteroids · Drug: Methotrexate

Interventions

  • Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 52 weeks.

    Also known as: RoActemra, Actemra

  • DrugDMARDs

    Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study. The study protocol does not specify any particular therapy.

  • DrugOral Corticosteroids

    Stable oral corticosteroids doses (≤10 mg/day prednisone or equivalent) are allowed. The study protocol does not specify any additional detail on types of oral corticosteroids.

  • Methotrexate per investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2

    DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR greater than or equal to (≥) 2.6 to less than or equal to (≤) 3.2 implied low disease activity, greater than (\>) 3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and less than (\<) 2.6 implied clinical remission.

    Time frame: Baseline, Week 2

  2. Change From Baseline in DAS28-ESR at Week 4

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 4

  3. Change From Baseline in DAS28-ESR at Week 8

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 8

  4. Change From Baseline in DAS28-ESR at Week 12

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 12

  5. Change From Baseline in DAS28-ESR at Week 16

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 16

  6. Change From Baseline in DAS28-ESR at Week 20

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 20

  7. Change From Baseline in DAS28-ESR at Week 24

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 24

  8. Change From Baseline in DAS28-ESR at Week 28

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 28

  9. Change From Baseline in DAS28-ESR at Week 32

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 32

  10. Change From Baseline in DAS28-ESR at Week 36

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 36

  11. Change From Baseline in DAS28-ESR at Week 40

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 40

  12. Change From Baseline in DAS28-ESR at Week 44

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 44

  13. Change From Baseline in DAS28-ESR at Week 48

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 48

  14. Change From Baseline in DAS28-ESR at Week 52

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, Week 52

  15. Change From Baseline in DAS28-ESR at Early Withdrawal

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

    Time frame: Baseline, early withdrawal (up to Week 52)

Secondary outcomes

  1. Number of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response

    A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  2. Number of Participants Achieving an ACR50 Response

    A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  3. Number of Participants Achieving an ACR70 Response

    A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  4. Number of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR

    DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  5. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

    The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI ≤3.3 indicates clinical remission, \>3.3 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  6. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

    The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI ≤2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  7. Percent Change From Baseline in Total TJC on 68 Joints at Week 52

    Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 68. A reduction in number of tender joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).

    Time frame: Baseline, Week 52

  8. Change From Baseline in Total TJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

    Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of tender joints compared to baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  9. Percent Change From Baseline in Total SJC on 66 Joints at Week 52

    Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 66. A reduction in number of swollen joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).

    Time frame: Baseline, Week 52

  10. Change From Baseline in Total SJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

    Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of swollen joints compared to baseline indicates improvement.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  11. Number of Participants Who Achieved Low Disease Activity as Defined by DAS28-ESR ≤3.2

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  12. Number of Participants Who Achieved Remission as Defined by DAS28-ESR <2.6

    DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR \<2.6 implied clinical remission.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  13. Number of Participants With Non-Biologic DMARD/Corticosteroid Dose Reductions and/or Discontinuation

    Results are reported for number of participants who had non-biologic DMARD/corticosteroid dose reductions and/or discontinuation by reasons for dose reductions or discontinuation (safety reasons, discomfort, lack of efficacy, other reasons, and unknown reasons). Participants may be included under more than one reason.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, at early withdrawal (up to Week 52), follow-up Week 4 (up to Week 56), and follow-up Week 8 (up to Week 60)

  14. Percentage of Methotrexate Adherence as Assessed by Methotrexate Adherence Questionnaire

    Methotrexate adherence was determined from responses to the question 'Over the last 3 months you were prescribed 12 doses of methotrexate, how many (approximately) have you taken?' Adherence (%) was calculated as: (Approximate number of doses taken/12)\*100.

    Time frame: Baseline, Weeks 12, 24, 36, 52, and at early withdrawal (up to Week 52)

  15. Patient Global Assessment of Disease Activity VAS Score

    Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  16. Patient Pain VAS Score

    This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  17. Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  18. Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

    The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score).

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  19. Number of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records

    A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.

    Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)

  20. Number of Participants With Anti-Tocilizumab Antibodies

    Time frame: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)

  21. Serum Levels of Tocilizumab

    Time frame: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)

  22. Serum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)

    Time frame: Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)

07

Results

Posted Dec 7, 2018

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Started22140
Received at least 1 dose of tocilizumab21140
Completed765
Not completed1575
Withdrew: Other1166
Withdrew: Protocol violation01
Withdrew: Participant/legal guardian decision13
Withdrew: Physician decision21
Withdrew: Lost to follow-up12
Withdrew: Death01
Withdrew: Adverse event01

Outcome measures

PrimaryChange From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2

DAS28 was calculated from swollen joint count (SJC) and tender joint count (TJC) using 28 joints count, erythrocyte sedimentation rate (ESR; millimeters per hour \[mm/hour\]), and patient's global assessment of disease activity (measured on a 0 to 100 mm Visual Analog Scale \[VAS\] where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR greater than or equal to (≥) 2.6 to less than or equal to (≤) 3.2 implied low disease activity, greater than (\>) 3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and less than (\<) 2.6 implied clinical remission.

Time frame:
Baseline, Week 2
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) at Week 2
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline5.52 ± 1.0145.53 ± 1.257
Change at Week 2-1.41 ± 0.994-1.22 ± 1.131
PrimaryChange From Baseline in DAS28-ESR at Week 4

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 4
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 4
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 4-1.86 ± 1.016-2.11 ± 1.215
PrimaryChange From Baseline in DAS28-ESR at Week 8

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 8
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 8
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 8-2.42 ± 1.352-2.62 ± 1.482
PrimaryChange From Baseline in DAS28-ESR at Week 12

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 12
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 12-2.33 ± 1.522-2.99 ± 1.510
PrimaryChange From Baseline in DAS28-ESR at Week 16

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 16
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 16-2.93 ± 1.218-3.07 ± 1.532
PrimaryChange From Baseline in DAS28-ESR at Week 20

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 20
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 20
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 20-3.17 ± 1.346-3.13 ± 1.525
PrimaryChange From Baseline in DAS28-ESR at Week 24

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 24
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 24
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 24-3.28 ± 1.379-3.33 ± 1.470
PrimaryChange From Baseline in DAS28-ESR at Week 28

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 28
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 28
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 28-3.54 ± 1.260-3.32 ± 1.552
PrimaryChange From Baseline in DAS28-ESR at Week 32

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 32
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 32
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 32-3.19 ± 1.418-3.54 ± 1.448
PrimaryChange From Baseline in DAS28-ESR at Week 36

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 36
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 36
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 36-3.57 ± 1.358-3.55 ± 1.589
PrimaryChange From Baseline in DAS28-ESR at Week 40

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 40
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 40
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 40-3.82 ± 1.143-3.64 ± 1.524
PrimaryChange From Baseline in DAS28-ESR at Week 44

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 44
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 44
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 44-3.61 ± 1.325-3.65 ± 1.574
PrimaryChange From Baseline in DAS28-ESR at Week 48

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 48
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 48
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 48-3.54 ± 1.146-3.65 ± 1.552
PrimaryChange From Baseline in DAS28-ESR at Week 52

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, Week 52
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Week 52
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Week 52-3.75 ± 1.361-3.67 ± 1.592
PrimaryChange From Baseline in DAS28-ESR at Early Withdrawal

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity, \>3.2 to ≤5.1 implied moderate disease activity, \>5.1 implied high/severe disease, and \<2.6 implied clinical remission.

Time frame:
Baseline, early withdrawal (up to Week 52)
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR at Early Withdrawal
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Change From Baseline in DAS28-ESR at Early Withdrawal-2.88 ± 1.236-1.63 ± 1.480
SecondaryNumber of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response

A participant had an ACR20 response if there was at least a 20 percent (%) improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either C-reactive protein \[CRP\] or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants Achieving an American College of Rheumatology Criteria 20 (ACR20) Response
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Week 2623
Week 4668
Week 81169
Week 121083
Week 161383
Week 201586
Week 241590
Week 281487
Week 321389
Week 361292
Week 401391
Week 441288
Week 481287
Week 521288
Early withdrawal310
SecondaryNumber of Participants Achieving an ACR50 Response

A participant had an ACR50 response if there was at least a 50% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants Achieving an ACR50 Response
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Week 205
Week 4320
Week 8643
Week 12854
Week 16762
Week 20961
Week 24964
Week 281368
Week 32869
Week 36974
Week 40971
Week 441072
Week 481173
Week 52873
Early withdrawal24
SecondaryNumber of Participants Achieving an ACR70 Response

A participant had an ACR70 response if there was at least a 70% improvement, ie, reduction from Baseline, in TJC (68 joints) and SJC (66 joints) and in at least 3 of the following 5 parameters: 1) Physician's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 2) Patient's Global Assessment of Disease Activity \[VAS: 0 mm=no disease activity to 100 mm=maximum disease activity\]; 3) Patient's Assessment of Pain \[VAS: 0 mm=no pain to 100 mm=unbearable pain\]; 4) Health Assessment Questionnaire \[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, averaged to 0=without difficulty to 3=unable to do\] and 5) an acute-phase reactant (either CRP or ESR).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants Achieving an ACR70 Response
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Week 200
Week 419
Week 8419
Week 12330
Week 16332
Week 20737
Week 24538
Week 28644
Week 32647
Week 36748
Week 40849
Week 44653
Week 48856
Week 52754
Early withdrawal21
SecondaryNumber of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR

DAS28-ESR was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (VAS: 0 mm=no disease activity to 100 mm=maximum disease activity). DAS28-ESR scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. The DAS28-ESR based EULAR response criteria were used to measure individual response as none, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached. Good responders had a change from baseline \>1.2 with a DAS28 score ≤3.2; moderate responders had a change from baseline \>1.2 with a DAS28 score \>3.2 or a change from baseline \>0.6 to ≤1.2 with a DAS28 score ≤5.1. Participants with change from baseline \>0.6 to ≤1.2 with a DAS28 score \>5.1, or any score with change from baseline ≤0.6, were assessed as non-responders.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants With European League Against Rheumatism (EULAR) Response (Good, Moderate or No Response) Based on DAS28-ESR
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Week 2: No response456
Week 2: Moderate response1056
Week 2: Good response725
Week 4: No response322
Week 4: Moderate response758
Week 4: Good response1157
Week 8: No response111
Week 8: Moderate response948
Week 8: Good response872
Week 12: No response411
Week 12: Moderate response334
Week 12: Good response1283
Week 16: No response19
Week 16: Moderate response430
Week 16: Good response1386
Week 20: No response09
Week 20: Moderate response527
Week 20: Good response1485
Week 24: No response17
Week 24: Moderate response221
Week 24: Good response1689
Week 28: No response15
Week 28: Moderate response024
Week 28: Good response1886
Week 32: No response13
Week 32: Moderate response221
Week 32: Good response1691
Week 36: No response04
Week 36: Moderate response319
Week 36: Good response1591
Week 40: No response02
Week 40: Moderate response115
Week 40: Good response1694
Week 44: No response05
Week 44: Moderate response215
Week 44: Good response1587
Week 48: No response04
Week 48: Moderate response213
Week 48: Good response1490
Week 52: No response05
Week 52: Moderate response312
Week 52: Good response1290
Early Withdrawal: No response011
Early Withdrawal: Moderate response18
Early Withdrawal: Good response49
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician global assessment of disease activity assessed on 0-10 centimeter (cm) VAS (0 cm= no disease activity and 10 cm= worst disease activity), and CRP in milligrams per liter (mg/L). SDAI total score = 0-86. SDAI ≤3.3 indicates clinical remission, \>3.3 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline31.23 ± 11.89232.33 ± 11.620
Change at Week 2-9.80 ± 10.406-6.94 ± 9.710
Change at Week 4-12.64 ± 10.502-13.92 ± 10.666
Change at Week 8-19.75 ± 12.978-17.21 ± 12.900
Change at Week 12-14.65 ± 15.003-20.26 ± 12.739
Change at Week 16-19.48 ± 9.649-21.16 ± 11.945
Change at Week 20-23.67 ± 14.015-20.50 ± 11.630
Change at Week 24-24.31 ± 13.469-23.48 ± 12.417
Change at Week 28-24.87 ± 12.554-23.26 ± 12.418
Change at Week 32-22.98 ± 12.850-24.94 ± 11.399
Change at Week 36-26.32 ± 12.795-24.65 ± 11.268
Change at Week 40-27.29 ± 13.280-25.46 ± 12.210
Change at Week 44-27.71 ± 12.851-26.08 ± 11.835
Change at Week 48-26.83 ± 13.615-26.13 ± 11.189
Change at Week 52-27.45 ± 14.351-26.15 ± 12.791
Change at early withdrawal-18.94 ± 14.681-9.45 ± 12.533
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

The CDAI is the numerical sum of four outcome parameters: TJC and SJC based on a 28-joint assessment, patient and physician's global assessment of disease activity assessed on 0-10 cm VAS (0 cm= no disease activity and 10 cm= worst disease activity). CDAI total score = 0-76. CDAI ≤2.8 indicates clinical remission, \>2.8 to 10 = low disease activity, \>10 to 22 = moderate disease activity, and \>22 = high (or severe) disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline29.69 ± 11.20930.88 ± 10.953
Change at Week 2-8.35 ± 10.433-5.16 ± 9.323
Change at Week 4-11.87 ± 10.062-12.26 ± 10.137
Change at Week 8-17.74 ± 12.289-15.63 ± 11.873
Change at Week 12-15.39 ± 14.216-18.66 ± 11.895
Change at Week 16-20.70 ± 11.694-19.51 ± 11.124
Change at Week 20-22.19 ± 13.545-19.23 ± 11.433
Change at Week 24-22.88 ± 12.720-21.96 ± 11.825
Change at Week 28-23.43 ± 11.573-21.48 ± 11.585
Change at Week 32-21.55 ± 12.019-23.20 ± 10.842
Change at Week 36-24.86 ± 11.854-23.10 ± 11.263
Change at Week 40-25.74 ± 12.488-24.01 ± 11.282
Change at Week 44-25.42 ± 11.971-24.42 ± 11.186
Change at Week 48-25.36 ± 12.718-24.59 ± 10.645
Change at Week 52-25.48 ± 13.049-24.42 ± 12.599
Change at early withdrawal-17.78 ± 14.667-8.68 ± 11.909
SecondaryPercent Change From Baseline in Total TJC on 68 Joints at Week 52

Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 68. A reduction in number of tender joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Total TJC on 68 Joints at Week 52
percent changeTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Percent Change From Baseline in Total TJC on 68 Joints at Week 52-83.12 ± 26.607-80.44 ± 41.226
SecondaryChange From Baseline in Total TJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of tender joints compared to baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · tender joints
Change From Baseline in Total TJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
tender jointsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline10.4 ± 6.4612.9 ± 7.06
Change at Week 2-3.4 ± 5.62-2.4 ± 5.63
Change at Week 4-3.9 ± 5.80-5.4 ± 6.14
Change at Week 8-6.6 ± 6.41-6.4 ± 6.94
Change at Week 12-6.0 ± 6.71-8.0 ± 7.35
Change at Week 16-7.9 ± 6.35-8.2 ± 7.05
Change at Week 20-8.5 ± 6.59-8.3 ± 7.09
Change at Week 24-8.3 ± 7.41-9.3 ± 7.53
Change at Week 28-8.7 ± 6.26-9.2 ± 7.04
Change at Week 32-7.6 ± 6.64-10.1 ± 6.76
Change at Week 36-9.4 ± 6.25-9.7 ± 7.23
Change at Week 40-10.1 ± 6.64-10.3 ± 6.74
Change at Week 44-9.7 ± 6.46-10.4 ± 6.63
Change at Week 48-9.6 ± 6.36-10.5 ± 6.70
Change at Week 52-9.4 ± 7.15-10.4 ± 8.01
Change at early withdrawal-7.0 ± 6.24-3.3 ± 7.46
SecondaryPercent Change From Baseline in Total SJC on 66 Joints at Week 52

Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 66. A reduction in number of swollen joints compared to baseline indicates improvement. The outcome is reported as the percent change from baseline to end of treatment (52 weeks).

Time frame:
Baseline, Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Total SJC on 66 Joints at Week 52
percent changeTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Percent Change From Baseline in Total SJC on 66 Joints at Week 52-89.31 ± 20.059-74.77 ± 66.277
SecondaryChange From Baseline in Total SJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal

Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1; total was calculated by adding all the joints for a maximum score of 28. A reduction in number of swollen joints compared to baseline indicates improvement.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · swollen joints
Change From Baseline in Total SJC on 28 Joints at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at Early Withdrawal
swollen jointsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline7.0 ± 4.645.6 ± 4.43
Change at Week 2-2.5 ± 4.31-0.8 ± 3.95
Change at Week 4-4.2 ± 3.79-2.5 ± 3.81
Change at Week 8-4.8 ± 4.21-3.2 ± 4.40
Change at Week 12-4.2 ± 4.37-3.8 ± 4.36
Change at Week 16-5.3 ± 4.67-3.9 ± 4.41
Change at Week 20-5.6 ± 5.08-4.2 ± 4.60
Change at Week 24-5.9 ± 5.12-4.7 ± 4.21
Change at Week 28-6.4 ± 4.90-4.4 ± 4.63
Change at Week 32-5.4 ± 5.10-4.8 ± 4.37
Change at Week 36-6.5 ± 4.57-4.9 ± 4.41
Change at Week 40-6.6 ± 5.12-5.0 ± 4.82
Change at Week 44-6.6 ± 5.28-5.2 ± 4.71
Change at Week 48-6.4 ± 4.83-5.0 ± 4.48
Change at Week 52-6.3 ± 4.81-5.1 ± 4.51
Change at early withdrawal-5.8 ± 5.59-1.7 ± 4.43
SecondaryNumber of Participants Who Achieved Low Disease Activity as Defined by DAS28-ESR ≤3.2

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR ≥2.6 to ≤3.2 implied low disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants Who Achieved Low Disease Activity as Defined by DAS28-ESR ≤3.2
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline05
Week 2718
Week 4930
Week 8325
Week 12623
Week 16320
Week 20315
Week 24215
Week 28415
Week 32514
Week 36114
Week 40314
Week 44510
Week 48312
Week 52011
Early withdrawal24
SecondaryNumber of Participants Who Achieved Remission as Defined by DAS28-ESR <2.6

DAS28 was calculated from SJC and TJC using 28 joints count, ESR (mm/hour), and patient's global assessment of disease activity (measured on a 0 to 100 mm VAS where 0 mm=no disease activity and 100 mm=worst disease activity). DAS28 scores were calculated as \[0.56 × square root of TJC\] + \[0.28 × square root of SJC\] + \[0.70 × natural log (ESR)\] + \[0.014 × VAS\]. Total score range: 0-10, higher score=higher disease activity. DAS28-ESR \<2.6 implied clinical remission.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants Who Achieved Remission as Defined by DAS28-ESR <2.6
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline03
Week 2115
Week 4234
Week 8553
Week 12666
Week 161072
Week 201175
Week 241476
Week 281473
Week 321280
Week 361480
Week 401381
Week 441080
Week 481178
Week 521280
Early withdrawal37
SecondaryNumber of Participants With Non-Biologic DMARD/Corticosteroid Dose Reductions and/or Discontinuation

Results are reported for number of participants who had non-biologic DMARD/corticosteroid dose reductions and/or discontinuation by reasons for dose reductions or discontinuation (safety reasons, discomfort, lack of efficacy, other reasons, and unknown reasons). Participants may be included under more than one reason.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, at early withdrawal (up to Week 52), follow-up Week 4 (up to Week 56), and follow-up Week 8 (up to Week 60)
Reported as:
Number · participants
Number of Participants With Non-Biologic DMARD/Corticosteroid Dose Reductions and/or Discontinuation
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline: Safety01
Baseline: Discomfort00
Baseline: Lack of efficacy01
Baseline: Other02
Baseline: Unknown00
Week 2: Safety04
Week 2: Discomfort00
Week 2: Lack of efficacy00
Week 2: Other07
Week 2: Unknown00
Week 4: Safety06
Week 4: Discomfort00
Week 4: Lack of efficacy01
Week 4: Other19
Week 4: Unknown01
Week 8: Safety08
Week 8: Discomfort00
Week 8: Lack of efficacy00
Week 8: Other113
Week 8: Unknown01
Week 12: Safety06
Week 12: Discomfort 802
Week 12: Lack of efficacy00
Week 12: Other214
Week 12: Unknown00
Week 16: Safety07
Week 16: Discomfort00
Week 16: Lack of efficacy01
Week 16: Other213
Week 16: Unknown00
Week 20: Safety06
Week 20: Discomfort00
Week 20: Lack of efficacy00
Week 20: Other29
Week 20: Unknown01
Week 24: Safety05
Week 24:Discomfort00
Week 24: Lack of efficacy00
Week 24: Other113
Week 24: Unknown01
Week 28: Safety03
Week 28: Discomfort00
Week 28: Lack of efficacy01
Week 28: Other17
Week 28: Unknown00
Week 32: Safety04
Week 32: Discomfort00
Week 32: Lack of efficacy02
Week 32: Other111
Week 32: Unknown00
Week 36: Safety03
Week 36: Discomfort01
Week 36: Lack of efficacy00
Week 36: Other23
Week 36: Unknown00
Week 40: Safety04
Week 40: Discomfort01
Week 40: Lack of efficacy01
Week 40: Other11
Week 40: Unknown00
Week 44: Safety03
Week 44: Discomfort00
Week 44: Lack of efficacy00
Week 44: Other07
Week 44: Unknown00
Week 48: Safety03
Week 48: Discomfort00
Week 48: Lack of efficacy01
Week 48: Other13
Week 48: Unknown00
Week 52: Safety00
Week 52: Discomfort00
Week 52: Lack of efficacy00
Week 52: Other01
Week 52: Unknown00
Early withdrawal: Safety00
Early withdrawal: Discomfort00
Early withdrawal: Lack of efficacy00
Early withdrawal: Other18
Early withdrawal: Unknown00
Follow-up Week 4: Safety00
Follow-up Week 4: Discomfort00
Follow-up Week 4: Lack of efficacy00
Follow-up Week 4: Other02
Follow-up Week 4: Unknown01
Follow-up Week 8: Safety00
Follow-up Week 8: Discomfort00
Follow-up Week 8: Lack of efficacy00
Follow-up Week 8: Other00
Follow-up Week 8: Unknown00
SecondaryPercentage of Methotrexate Adherence as Assessed by Methotrexate Adherence Questionnaire

Methotrexate adherence was determined from responses to the question 'Over the last 3 months you were prescribed 12 doses of methotrexate, how many (approximately) have you taken?' Adherence (%) was calculated as: (Approximate number of doses taken/12)\*100.

Time frame:
Baseline, Weeks 12, 24, 36, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · percentage of methotrexate adherence
Percentage of Methotrexate Adherence as Assessed by Methotrexate Adherence Questionnaire
percentage of methotrexate adherenceTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline96.82 ± 7.747
Week 1292.92 ± 14.412
Week 2491.54 ± 20.915
Week 3690.14 ± 21.456
Week 5295.28 ± 11.417
Early withdrawal90.69 ± 18.367
SecondaryPatient Global Assessment of Disease Activity VAS Score

Patient global assessment of disease activity was measured on a 0 to 100 mm horizontal VAS where 0 mm=no disease activity and 100 mm=maximum disease activity.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · mm
Patient Global Assessment of Disease Activity VAS Score
mmTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline59.6 ± 26.9462.3 ± 20.72
Week 250.3 ± 24.0154.5 ± 22.12
Week 446.4 ± 26.4342.3 ± 23.22
Week 835.8 ± 24.7336.2 ± 24.43
Week 1241.3 ± 27.6732.1 ± 23.91
Week 1629.6 ± 21.5929.2 ± 22.55
Week 2025.7 ± 23.7729.9 ± 22.99
Week 2423.8 ± 19.5526.6 ± 21.92
Week 2823.2 ± 16.4726.7 ± 23.12
Week 3224.0 ± 17.8124.3 ± 21.66
Week 3624.1 ± 19.1322.3 ± 21.86
Week 4022.5 ± 19.3121.4 ± 20.81
Week 4422.7 ± 20.6222.0 ± 22.83
Week 4822.9 ± 23.3118.9 ± 20.57
Week 5220.6 ± 18.9621.4 ± 23.07
Early withdrawal30.8 ± 28.7852.4 ± 24.88
SecondaryPatient Pain VAS Score

This assessment represents the participant's assessment of his/her current level of pain on a 100 mm horizontal VAS where 0 mm= no pain to 100 mm= unbearable pain.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · mm
Patient Pain VAS Score
mmTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline50.5 ± 23.7857.5 ± 21.06
Week 246.1 ± 22.4351.1 ± 22.58
Week 447.0 ± 26.6942.4 ± 23.80
Week 837.8 ± 25.7535.3 ± 24.30
Week 1240.9 ± 29.5630.8 ± 23.29
Week 1629.7 ± 20.8326.8 ± 22.61
Week 2027.6 ± 25.4828.6 ± 23.74
Week 2429.9 ± 22.7625.2 ± 22.16
Week 2824.8 ± 19.1525.6 ± 23.18
Week 3225.1 ± 17.9222.6 ± 21.30
Week 3629.6 ± 20.0322.1 ± 21.68
Week 4027.6 ± 22.7020.9 ± 21.24
Week 4426.7 ± 24.2520.0 ± 21.26
Week 4828.6 ± 28.9817.6 ± 19.66
Week 5222.4 ± 19.7019.0 ± 19.83
Early withdrawal30.4 ± 29.5751.6 ± 26.03
SecondaryHealth Assessment Questionnaire-Disability Index (HAQ-DI) Score

The HAQ-DI questionnaire measures functional status (disability) and health-related quality of life. It measures the participant's ability to perform everyday tasks. The index consists of 20 questions regarding the function of the upper and lower extremities. These questions are summarized in 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common activities over past week. Each question is evaluated according to the degree of severity on a 4-point scale. Total score for HAQ-DI was the average of all questions and ranges from 0 = without any difficulty to 3 = unable to do.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · units on a scale
Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline1.806 ± 0.55511.738 ± 0.6406
Week 21.558 ± 0.73191.659 ± 0.6210
Week 41.616 ± 0.77201.546 ± 0.7351
Week 81.508 ± 0.75971.404 ± 0.8115
Week 121.488 ± 0.93041.333 ± 0.8272
Week 161.351 ± 0.95861.312 ± 0.8621
Week 201.409 ± 0.90711.318 ± 0.8608
Week 241.330 ± 0.83791.261 ± 0.8915
Week 281.330 ± 0.94121.221 ± 0.8730
Week 321.351 ± 0.88161.232 ± 0.8870
Week 361.432 ± 0.90481.170 ± 0.8757
Week 401.479 ± 0.89751.199 ± 0.8908
Week 441.442 ± 0.93921.130 ± 0.9206
Week 481.361 ± 0.96851.114 ± 0.8815
Week 521.338 ± 0.97961.154 ± 0.9187
Early withdrawal1.252 ± 1.12321.756 ± 0.7820
SecondaryFunctional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score

The FACIT-F score was calculated according to a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function. FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-F score for a total possible score of 0 (worse score) to 52 (better score).

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Mean · units on a scale
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score
units on a scaleTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline18.4 ± 11.1424.3 ± 11.55
Week 223.1 ± 12.3727.9 ± 11.03
Week 425.1 ± 12.2830.7 ± 12.10
Week 830.2 ± 11.5832.8 ± 11.91
Week 1228.4 ± 11.7133.7 ± 11.85
Week 1631.3 ± 13.8034.0 ± 12.53
Week 2033.2 ± 13.5734.1 ± 12.05
Week 2433.8 ± 15.2835.3 ± 10.98
Week 2832.9 ± 12.0635.5 ± 11.59
Week 3234.1 ± 12.6836.2 ± 11.32
Week 3630.3 ± 13.6236.8 ± 11.48
Week 4031.7 ± 12.8737.1 ± 11.69
Week 4431.0 ± 14.0237.2 ± 11.75
Week 4831.6 ± 14.6337.9 ± 11.73
Week 5233.4 ± 14.1738.1 ± 11.16
Early withdrawal31.3 ± 2.6324.5 ± 12.08
SecondaryNumber of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records

A diary card was provided to participants to record home injections. Participants were asked to return all empty drug supply boxes, unused pre-filled syringe, and diary cards to the clinic at each visit as a measure of drug accountability and participant compliance. A participant was considered compliant if the participant correctly administered all scheduled doses of SC tocilizumab during the assessment period.

Time frame:
Baseline, Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, and at early withdrawal (up to Week 52)
Reported as:
Number · participants
Number of Participants Compliant to Tocilizumab Treatment as Measured by Diary Cards and Return Records
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline21137
Week 220126
Week 420132
Week 818124
Week 1218121
Week 1619120
Week 2018114
Week 2416107
Week 2819112
Week 3217111
Week 3617105
Week 4016104
Week 4416102
Week 4813107
Week 521698
Early withdrawal427
SecondaryNumber of Participants With Anti-Tocilizumab Antibodies
Time frame:
Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
Reported as:
Number · participants
Number of Participants With Anti-Tocilizumab Antibodies
participantsTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline36
Week 120—
Week 2402
Early withdrawal00
Follow-up visit00
SecondarySerum Levels of Tocilizumab
Time frame:
Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Serum Levels of Tocilizumab
micrograms per milliliter (mcg/mL)Tocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline0.0000 ± 0.00000.0082 ± 0.09619
Week 1235.3953 ± 22.6906940.2529 ± 21.05801
Week 2453.0416 ± 39.0636743.9047 ± 30.41603
Early withdrawal44.7160 ± 38.8152117.6160 ± 22.92477
Follow-up visit0.0597 ± 0.103352.3123 ± 7.40931
SecondarySerum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)
Time frame:
Baseline, Weeks 12 and 24, at early withdrawal (up to Week 52), and follow-up visit (8 weeks after last dose of tocilizumab, up to 60 weeks)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Serum Levels of Soluble Interleukin-6 Receptors (sIL-6Rs)
nanograms per milliliter (ng/mL)Tocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Baseline43.63 ± 10.94742.40 ± 12.087
Week 12577.42 ± 175.649548.70 ± 131.079
Week 24602.25 ± 158.541521.07 ± 160.464
Early withdrawal639.75 ± 99.644327.95 ± 229.481
Follow-up visit132.23 ± 93.048125.07 ± 211.038

Adverse events

Collected over Baseline up to Week 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Monotherapy—3/21 (14.3%)19/21 (90.5%)
Tocilizumab in Combination With Methotrexate or Other DMARDs—7/140 (5%)135/140 (96.4%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
PneumoniaInfections and infestations1/210/140
SinusitisInfections and infestations1/210/140
WoundInjury, poisoning and procedural complications1/210/140
VomitingGastrointestinal disorders1/210/140
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/210/140
Knee arthroplastySurgical and medical procedures1/210/140
Arthritis bacterialInfections and infestations0/211/140
CellulitisInfections and infestations0/211/140
Subcutaneous abscessInfections and infestations0/211/140
Accidental overdoseInjury, poisoning and procedural complications0/211/140
Most frequent other events
Showing 10 of 36
Most frequent other events
EventTocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDs
Lower respiratory tract infectionInfections and infestations6/2125/140
NasopharyngitisInfections and infestations5/2133/140
Urinary tract infectionInfections and infestations5/2116/140
DiarrhoeaGastrointestinal disorders2/2132/140
Alanine aminotransferase increasedInvestigations2/2131/140
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/2127/140
CoughRespiratory, thoracic and mediastinal disorders4/2121/140
HeadacheNervous system disorders4/2113/140
NauseaGastrointestinal disorders0/2121/140
Upper respiratory tract infectionInfections and infestations2/2120/140

Baseline characteristics

FAS population included all participants who received at least one dose of SC tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDsTotal
Mean53.9 ± 13.6355.3 ± 10.7655.1 ± 11.14
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab MonotherapyTocilizumab in Combination With Methotrexate or Other DMARDsTotal
Female16104120
Male53641
08

Study locations

38 sites
  • Aberdeen Royal Infirmary
    Aberdeen, AB25 2ZN, United Kingdom
  • Christchurch Hospital; Rheumatology
    Bournemouth, BH23 2JX, United Kingdom
  • Royal Sussex County Hospital; Clinical Investigation Research Unit
    Brighton, BN2 5BE, United Kingdom
  • Queens Hospital
    Burton on Trent, DE13 0RB, United Kingdom
  • West Suffolk Hospital
    Bury Saint Edmonds, IP33 2QZ, United Kingdom
  • Addenbrooke'S Hospital; Rheumatology Research Unit
    Cambridge, CB2 2QQ, United Kingdom
  • Cannock Chase Hospital; Rheumatology
    Cannock, WS11 5XY, United Kingdom
  • University Hospital of Wales; Dept of Rhematology
    Cardiff, CF14 4XW, United Kingdom
  • Broomfield Hospital
    Chelmsford, CM1 7ET, United Kingdom
  • Countess of Chester Hospital; Dept of Rheumatology
    Chester, CH2 1UL, United Kingdom
  • Dewsbury & District Hospital; Dept of Rheumatology
    Dewsbury, WF13 4HS, United Kingdom
  • Russells Hall Hospital; Rheumatology Department
    Dudley, DY1 2HQ, United Kingdom
  • Ninewells Hospital
    Dundee, DD12 9SY, United Kingdom
  • Eastbourne District General Hospital; Dept of Rheumatology
    Eastbourne, BN21 2UD, United Kingdom
  • Western General Hospital; Pharmacy Department
    Edinburgh, EH4 2XU, United Kingdom
  • Gartnavel General Hospital; Rheumatology
    Glasgow, G12 0YN, United Kingdom
  • Diana Princess of Wales Hosp.
    Grimsby, DN33 2BA, United Kingdom
  • Princess Alexandra Hospital
    Harlow, CM20 1QX, United Kingdom
  • Northwick Park Hospital
    Harrow, HA1 3UJ, United Kingdom
  • Hemel Hempstead General Hospital; Rheumatology Dept
    Hemel Hempstead, HP2 4AD, United Kingdom
  • Hull Royal Infirmary; Rheumatology Department
    Hull, HU3 3JZ, United Kingdom
  • Llandudno General Hospital
    Llandudno, LL30 1LB, United Kingdom
  • Whipps Cross Hospital; Rheumatology Dept
    London, E11 1NR, United Kingdom
  • Royal Free Hospital; Department of Rheumatology
    London, NW3 2QG, United Kingdom
  • Maidstone Hospital; Dept of Rheumatology
    Maidstone, ME16 9QQ, United Kingdom
  • Wythenshawe Hospital
    Manchester, M23 9QZ, United Kingdom
  • Freeman Hospital; Dept of Rheumatology
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
  • North Tyneside General Hospital
    North Shields, NE29 8NH, United Kingdom
  • Norfolk & Norwich Hospital; Rheumatology
    Norwich, NR4 7UY, United Kingdom
  • Integrated Care Centre
    Oldham, OL1 1NL, United Kingdom
  • Solihull Hospital
    Solihull, B91 2JL, United Kingdom
  • Haywood Hospital; Staffordshire Rheumatology Centre
    Stoke-on-trent, ST6 7AG, United Kingdom
  • Great Western Hospital; Dept of Rheumatology
    Swindon, SN3 6BB, United Kingdom
  • Torbay Hospital; Dept of Rhematology
    Torquay, TQ2 7AA, United Kingdom
  • Royal Cornwall Hospital; Rhuematololgy Dept
    Truro, TR1 3LJ, United Kingdom
  • Warrington Hospital
    Warrington, WA5 1QG, United Kingdom
  • Wrightington Hospital; Rheumatology
    Wigan, WN6 9EW, United Kingdom
  • Wishaw General Hospital
    Wishaw, ML2 0DP, United Kingdom
09

References and documents

Publications

  • Isaacs JD, Salih A, Sheeran T, Patel YI, Douglas K, McKay ND, Naisbett-Groet B, Choy E. Efficacy and safety of subcutaneous tocilizumab in rheumatoid arthritis over 1 year: a UK real-world, open-label study. Rheumatol Adv Pract. 2019 Apr 19;3(1):rkz010. doi: 10.1093/rap/rkz010. eCollection 2019. PubMed 31431998 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2014 to primary completion in Aug 2016, 29 months.

Results were first posted in Dec 2018, 2 years 4 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 29 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2014
First posted
Jan 28, 2014
StartActual
Mar 4, 2014
Primary completionActual
Aug 4, 2016
CompletionActual
Aug 4, 2016
Results first posted
Dec 7, 2018
Last update
Dec 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02046603
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 28, 2014
Start date
Mar 4, 2014
Primary completion
Aug 4, 2016
Completion
Aug 4, 2016
Results posted
Dec 7, 2018
Last update
Dec 7, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion